학술논문
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Document Type
article
Author
Marie Maerevoet; Josee M. Zijlstra; George Follows; Rene-Olivier Casasnovas; J. S. P. Vermaat; Nagesh Kalakonda; Andre Goy; Sylvain Choquet; Eric Van Den Neste; Brian Hill; Catherine Thieblemont; Federica Cavallo; Fatima De la Cruz; John Kuruvilla; Nada Hamad; Ulrich Jaeger; Paolo Caimi; Ronit Gurion; Krzysztof Warzocha; Sameer Bakhshi; Juan-Manuel Sancho; Michael Schuster; Miklos Egyed; Fritz Offner; Theodoros P. Vassilakopoulos; Priyanka Samal; Matthew Ku; Xiwen Ma; Kelly Corona; Kamal Chamoun; Jatin Shah; Sharon Shacham; Michael G. Kauffman; Miguel Canales
Source
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of